Key clinical and health preference data

ParametersValuesReference
Log-logistic survival model of PFS of sunitinibScale = 0.01302; Shape = 1.174; r2 = 0.9997[12]
Log-logistic survival model of PFS of nivolumab plus ipilimumabScale = 0.02487; Shape = 0.9312; r2 = 0.9995[12]
Weibull survival model of OS of sunitinib armScale = 0.00685; Shape = 0.9778; r2 = 0.9939[12]
Weibull survival model of OS of nivolumab plus ipilimumabScale = 0.00414; Shape = 0.9938; r2 = 0.9993[12]
Probability (%) of total AEs (grade 1 and 2)
 Sunitinib34 (Range:26–43)[12]
 Nivolumab plus Ipilimumab47 (Range:59–12)[12]
Probability (%) of total AEs (grade ≥ 3)
 Sunitinib63 (Range:47–79)[12]
 Nivolumab plus Ipilimumab46 (Range:35–58)[12]
Probability (%) of fatigue (grade ≥ 3)
 Sunitinib9.2 (Range:6.9–11.4)[12]
 Nivolumab plus Ipilimumab4.2 (Range:3.2–5.3)[12]
Probability (%) of hypertension (grade ≥ 3)
 Sunitinib15.9 (Range:11.9–19.9)[12]
 Nivolumab plus Ipilimumab0.7 (Range:0.5–0.9)[12]
Probability (%) of anemia (grade ≥ 3)
 Sunitinib4.5 (Range:3.4–5.6)[12]
 Nivolumab plus Ipilimumab0.4 (Range:0.3–0.5)[12]
Probability (%) of palmar–plantar erythrodysesthesia (grade ≥ 3)
 Sunitinib9.2 (Range:6.9–11.4)[12]
 Nivolumab plus Ipilimumab0 (Range:0–0)[12]
Probability (%) of thrombocytopenia (grade ≥ 3)
 Sunitinib4.7 (Range:3.5–5.8)[12]
 Nivolumab plus Ipilimumab0 (Range:0–0)[12]
Proportion (%) of receiving active second-line treatment[19–21]
 US66 (Range:7.5–80)
 UK15.8 (Range:7.5–80)
 China33 (Range:7.5–80)
Health preferences
 Utility of PFS0.78 (Range:0.71–0.849)[24, 29, 41, 42]
 Utility of PD0.66 (Range:0.45–0.823)[24, 29, 41, 42]
 Disutility due to AEs (grade 1 and 2)0.014 (Range:0.008–0.02)[41]
 Disutility due to AEs (grade ≥ 3)0.157 (Range:0.11–0.204)[41]

Abbreviations: AE, adverse event; PD, progressed disease; PFS, progression-free survival; OS, overall survival